Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL33422 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL9705682 | 1.00 | SLC34A1 (0.46) | — | |
| Phosphoric Acid SCHEMBL10950125 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL2119223 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL2042899 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL18832328 | 0.94 | SLC34A1 (0.42) | — | |
| Phosphoric Acid SCHEMBL6133335 | 0.94 | SLC34A1 (0.42) | — | |
| Phosphoric Acid SCHEMBL10950121 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL4899513 | 0.94 | SLC34A1 (0.42) | — | |
| Phosphoric Acid SCHEMBL10874112 | 0.94 | SLC34A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069620-A1 | IMMUNOTHERAPEUTIC PHOSPHOLIPIDS FOR CANCER TREATMENT | UNIVERSITY OF CINCINNATI (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4646235-A1 | ALPHA-EMITTING RADIONUCLIDES FOR USE IN THE TREATMENT OF PERITONEAL CANCER | Oncoinvent AS (NO) | 2025-11-12 | — | — | EP | disclosed |
| EP-2614369-B2 | METHOD FOR DETERMINING THE SUITABILITY OF INHIBITORS OF HUMAN EZH2 IN TREATMENT | EPIZYME INC (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20250109123-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2025-04-03 | — | — | US | disclosed |
| CN-118515653-B | EZH2 specific inhibitor and preparation method and application thereof | 西湖制药(杭州)有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240293419-A1 | COMBINATION THERAPY FOR TREATING CANCER | EPIZYME INC (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240293418-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2024-09-05 | — | — | US | disclosed |
| US-20240277721-A1 | COMBINATION THERAPY FOR TREATING CANCER | EPIZYME INC (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118515653-A | EZH2 specific inhibitor and preparation method and application thereof | 西湖制药(杭州)有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-11407998-B2 | Twist signaling inhibitor compositions and methods of using the same | CITY OF HOPE (US) | 2022-08-09 | — | — | US | disclosed |
| EP-4031566-A1 | NKG2D FUSION PROTEINS AND USES THEREOF | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| EP-4031123-A1 | COMPOSITIONS FOR USE IN INHIBITING SRC KINASE AND TREATING AND PREVENTING ASSOCIATED DISORDERS | Enzene Biosciences Limited (IN) | 2022-07-27 | — | — | EP | disclosed |
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11370781-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-11332530-B2 | Determinants of cancer response to immunotherapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-17 | — | — | US | disclosed |
| US-11306068-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2022-04-19 | — | — | US | disclosed |
| WO-2022056491-A1 | TREATMENT METHODS | GENOCEA BIOSCIENCES, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-11230599-B2 | Tumor mutational load | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-01-25 | — | — | US | disclosed |